StackItSmart

Compound reference

Oxiracetam

Other compounds1 cited findingClinical review: not reviewed

Pharmacokinetics

Human observational studyAbstract inspected

In four healthy volunteers given single 2000 mg intravenous and oral doses, more than 90% of the intravenous dose was recovered unchanged in urine within 48 hours, and oral absolute bioavailability was 75% plus or minus 7%. Intravenous mean residence times ranged from 3.9 to 6.5 hours; the abstract reports residence times, volumes of distribution and clearance, which should not be relabeled as elimination half-lives.[1]

  • Very small pharmacokinetic study (n=4); no cognitive benefit or safety in renal impairment established.
  • No PMCID or other open-access full text was identified for this 1984 paper; abstract-only inspection could not be upgraded despite a search.
  • Abstract-checked; no qualified clinical review.
Inspection history

Clinical review: not reviewed by a qualified clinician.

· Prior batch record retained as unverified historical input pending fresh review.

· nootropic batch: reopened source(s) via NCBI E-utilities / PMC Open Access; verified and refined with precise numbers/limitations from the source.

What remains unresolved

Editorial assessment

These notes describe the scope of this review. Linked PMIDs are audit identifiers; an identifier alone does not verify a claim.

Narrowly supported passages published with study/product limits; remaining inherited assertions withheld from established-fact displays.

  • Not a comprehensive systematic review. Original monograph topics beyond the individual published claims—including monitoring schedules, contraindication lists, recovery assurances and detailed mechanisms—remain unverified.
  • No qualified clinician has reviewed these claims. Long-term outcomes and all marketed formulations have not been fully assessed.

This reference does not supply a dosing plan, monitoring timetable or recovery regimen. Discuss personal symptoms, medicines and laboratory results with a qualified clinician.

Explore the interaction evidence for this compound →

References

  1. Pharmacokinetics of oxiracetam following intravenous and oral administration in healthy volunteers.

    Perucca E, Albrici A, Gatti G, Spalluto R, Visconti M, Crema A. Eur J Drug Metab Pharmacokinet. 1984 Jul-Sep;9(3):267-74. DOI: 10.1007/BF03189650. 1984. PMID:6519128 · DOI:10.1007/BF03189650 Abstract only.

    Inspected location: PubMed/MEDLINE abstract (full Methods/Results text) via NCBI E-utilities efetch

    Study context and inspection record

Source inspection and clinical review are separate. An abstract check is not a full-text review. The records above identify what was actually inspected and do not certify the complete literature.

Recorded verification attempts
  • Fresh PubMed EUtils retrieval for inherited lead PMID 6519128; identity, abstract and linked corrections checked where an abstract existed.
  • https://pubmed.ncbi.nlm.nih.gov/6519128/ — abstract; PubMed abstract: Human pharmacokinetic results: unchanged urinary recovery, oral absorption and residence times

View this compound in the research library →

Related records in this class

Grouped under Other compounds for navigation only. Shared class membership does not make findings, formulations or evidence interchangeable between records.

StackItSmart

Age confirmation

This reference discusses steroids, SARMs and other compounds. It is educational, not medical advice, and does not recommend using or combining them.

Your confirmation is saved in this browser when storage is available.